Swiss drugmaker Novartis on Friday stepped up its challenge to Roche’s multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival’s drug Ocrevus.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,